CLINICAL_TRIALS ClinicalTrials.gov record update

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05052372
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:52.233786+00:00
Published At: 2022-12-22T00:00:00+00:00
Record Updated At: 2022-12-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Bladder Cancer", "Urothelial Carcinoma", "Transitional Cell Carcinoma", "Platinum-Resistant Urothelial Carcinoma", "Bladder Urothelial Carcinoma", "FGFR Mutation", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "FGFR2 Amplification", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Bladder Carcinoma", "Refractory Bladder Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-12-22"
protocolSection.identificationModule.nctId: "NCT05052372"
protocolSection.identificationModule.officialTitle: "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.